AI English summary of an SEC filing — figures as filed
CVS Health CVSCVS Health entered into an Underwriting Agreement with Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters on August 11, 2025, pursuant to which the company agreed to issue and sell 4 series of Senior Notes due 2032, 2035, 2055 and 2065 with interest rates of 5.000%, 5.450%, 6.200% and 6.250%, respectively.
Key points
AI summaryCVS Health entered into an Underwriting Agreement with Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters on August 11, 2025, pursuant to which the company agreed to issue and sell 4 series of Senior Notes due 2032, 2035, 2055 and 2065 with interest rates of 5.000%, 5.450%, 6.200% and 6.250%, respectively.
The company agreed to issue and sell an aggregate principal amount of $750,000,000 of Senior Notes due 2032, $1,500,000,000 due 2035, $1,250,000,000 due 2055 and $500,000,000 due 2065.
The company said the Notes were issued on August 15, 2025, and the net proceeds to the company from the sale of the Notes, after deducting the Underwriters' discounts and the estimated offering expenses payable by the company, are approximately $3,958,207,500.
CVS Health said it issued the Notes with Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters, pursuant to its Registration Statement on Form S-3ASR and a Senior Indenture dated August 15, 2006.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Agreement to Issue 4 Series of Senior Notes Due 2032, 2035, 2055 and 2065
CVS Health entered into an Underwriting Agreement with Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters on August 11, 2025, pursuant to which the company agreed to issue and sell 4 series of Senior Notes due 2032, 2035, 2055 and 2065 with interest rates of 5.000%, 5.450%, 6.200% and 6.250%, respectively.
Source · Based on the filing body and exhibits
Aggregate Principal Amount by Series
The company agreed to issue and sell an aggregate principal amount of $750,000,000 of Senior Notes due 2032, $1,500,000,000 due 2035, $1,250,000,000 due 2055 and $500,000,000 due 2065.
Source · Based on the filing body and exhibits
Issuance Date and Net Proceeds
The company said the Notes were issued on August 15, 2025, and the net proceeds to the company from the sale of the Notes, after deducting the Underwriters' discounts and the estimated offering expenses payable by the company, are approximately $3,958,207,500.
Source · Based on the filing body and exhibits
Underwriters and Governing Documents
CVS Health said it issued the Notes with Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters, pursuant to its Registration Statement on Form S-3ASR and a Senior Indenture dated August 15, 2006.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…